viru
remov
protein
affin
chromatographi
inactiv
capac
acid
ph
combin
high
temperatur
chaotrop
agent
determin
work
model
virus
studi
sendaiviru
human
immunodefic
viru
hiviiib
human
polioviru
typeii
human
herpesviru
canin
parvoviru
protein
affin
chromatographi
show
maximum
reduct
factor
log
case
virus
larger
nm
size
small
virus
nm
maximum
reduct
factor
log
non
viral
inactiv
observ
monoclon
antibodi
elut
step
low
ph
treatment
show
maximum
inactiv
factor
log
envelop
virus
howev
weak
inactiv
factor
log
obtain
dna
nonenvelop
virus
combin
high
temperatur
kscn
show
high
inactiv
factor
virus
studi
total
clearanc
factor
log
sendaiviru
hiviiib
human
polioviru
typeii
human
herpesviru
canin
parvoviru
respect
despit
rigor
control
appli
biotechnolog
product
process
contamin
virus
common
featur
biolog
product
viral
contamin
biolog
may
occur
sourc
materi
eg
cell
bank
anim
origin
human
blood
human
anim
tissu
adventiti
agent
introduc
product
process
eg
use
anim
sera
mammalian
cell
cultur
reason
process
valid
becom
import
tool
evalu
biopharmaceut
product
process
mammalianderiv
product
viru
valid
provid
high
level
assur
final
product
free
contamin
kind
studi
involv
spike
scale
downstream
process
highli
infecti
viru
titer
evalu
removalinactiv
abil
whole
process
process
step
reduc
virus
necessari
valid
everi
individu
step
given
manufactur
process
step
like
contribut
inactiv
remov
viru
need
subject
valid
studi
larzul
model
relev
virus
need
evalu
repres
potenti
viral
contamin
start
materi
tabl
anoth
critic
element
viral
valid
process
valid
scale
demonstr
comparison
process
paramet
ph
temperatur
biosepar
variabl
eg
resid
time
elut
profil
specif
activ
etc
due
risk
viral
contamin
viru
valid
studi
perform
laboratori
physic
separ
largescal
product
facil
work
studi
clearanc
factor
protein
affin
chromatographi
acid
ph
combin
high
temperatur
chaotrop
agent
product
recombin
hepat
b
viru
vaccin
monoclon
antibodi
mab
igg
specif
determin
recombin
hepat
b
surfac
antigen
rhbsag
de
et
al
mab
use
immunoligand
downstream
purif
process
rhbsag
employ
commerci
avail
recombin
hepat
b
viru
vaccin
heberbiovac
heber
biotec
sa
cuba
n
et
al
agraz
et
al
ascit
obtain
specif
pathogen
free
balbc
mice
previous
submit
rigor
microbiolog
control
viral
infect
icla
refer
center
rodent
virus
nijmegen
holland
design
propos
purif
monoclon
antibodi
combin
sever
step
includ
select
purif
protein
affin
chromatographi
fig
rhbsag
obtain
previous
describ
hardi
et
al
briefli
recombin
pichia
pastori
yeast
strain
kept
care
control
multipl
condit
harvest
yeast
cell
disrupt
et
al
recov
purifi
rhbsag
seri
wellestablish
step
includ
acid
precipit
et
al
adsorptiondesorpt
diatomac
earth
matrix
final
success
purif
immunoaffin
ion
exchang
gelfiltr
chromatograph
procedur
n
et
al
clearanc
studi
perform
laboratori
separ
product
facil
scale
three
step
potenti
abl
remov
andor
inactiv
viral
charg
protein
affin
chromatographi
low
ph
treatment
heat
presenc
kscn
ph
viru
reduct
factor
r
calcul
individu
accord
follow
formula
v
v
volum
start
postprocess
materi
respect
c
c
viru
concentr
start
postprocess
materi
respect
overal
clearanc
factor
calcul
sum
individu
remov
inactiv
factor
hageman
model
virus
use
viral
valid
studi
hiviiib
human
herpesviru
canin
parvoviru
human
polioviru
type
ii
sendaiviru
see
tabl
cover
wide
rang
physicalchem
structur
characterist
murin
virus
accord
regulatori
cytopath
effect
determin
valu
tissu
cultur
infecti
dose
ml
calcul
follow
reed
muench
method
reed
muench
sensit
limit
assay
tcid
ml
eight
experiment
determin
per
three
repli
reduct
inactiv
experi
use
criterion
assay
cell
line
use
hiv
neg
vero
mdk
lfkb
cultur
serum
contain
medium
co
sever
day
accord
time
need
viru
express
cytopath
effect
cell
cultur
materi
reagent
use
assay
came
gibco
grand
island
usa
tabl
show
paramet
consid
scale
protein
affin
chromatographi
step
determin
puriti
elut
mab
sdspage
process
yield
specif
activ
mab
elisa
princip
compar
criteria
defin
process
reproduc
protocol
assay
previous
describ
et
al
fifti
ml
semipurifi
materi
individu
load
virus
appli
protein
affin
column
ml
amershampharmacia
biotech
upssala
sweden
pack
c
column
previous
equilibr
mm
phosphat
buffer
ph
subsequ
matrix
wash
buffer
mab
elut
mm
citric
acid
ph
sampl
neutral
addit
tri
measur
viru
cytopath
effect
depend
maximum
titer
obtain
viru
appli
differ
quantiti
virus
mention
column
viru
remov
evalu
initi
titer
sendaiviru
hiviiib
human
herpesviru
human
polioviru
type
ii
canin
parvoviru
respect
viral
inactiv
low
ph
studi
carri
incub
sampl
mab
contain
viru
h
mm
citric
acid
ph
take
sampl
viru
model
inocul
ml
elut
antigen
incub
h
temperatur
reduc
cytopath
effect
measur
viru
initi
titer
sendaiviru
hiviiib
human
herpesviru
human
polioviru
type
ii
canin
parvoviru
respect
measur
virus
detect
cytopath
effect
includ
parvo
polioviru
method
disadvantag
cultur
specificinfect
andor
replic
effect
depend
specif
viru
strain
quantit
broad
rang
specif
detect
low
level
viral
contamin
shown
tabl
process
yield
puriti
specif
activ
mab
obtain
laboratori
scale
similar
result
obtain
larg
scale
evalu
abil
protein
affin
chromatographi
remov
model
virus
previous
show
tabl
distribut
viral
amount
onto
column
shown
tabl
due
specif
interact
protein
mab
matrix
abl
remov
sendaiviru
hiviiib
human
herpesviru
respect
initi
viral
charg
hypothes
charg
region
viral
envelop
would
interact
protein
media
high
reduct
factor
coincid
result
report
author
darl
spaltro
addit
nonenvelop
virus
behav
differ
envelop
virus
observ
reduct
factor
human
polioviru
type
ii
canin
parvoviru
respect
behavior
nonenvelop
virus
explain
sole
hypothesi
certain
kind
virus
could
interact
matrix
mean
electrostat
bind
posit
charg
present
viral
envelop
glycoprotein
result
seem
suggest
chromatograph
matrix
could
also
function
gel
filtrat
matrix
possibl
virus
rang
nm
trap
sepharos
consequ
viral
particl
may
easili
remov
inner
solid
phase
increas
quantiti
wash
buffer
prior
elut
step
differenti
unspecif
elut
mab
elut
could
solv
problem
addit
find
inactiv
viru
chromatograph
column
import
observ
forc
us
use
acid
ph
inactiv
agent
protein
affin
chromatographi
consequ
remov
inactiv
factor
obtain
affin
acid
ph
step
respect
analyz
individu
work
differ
mechan
increas
cumul
clearanc
factor
whole
purif
process
howev
longer
resid
time
min
could
favor
inactiv
process
insid
column
allow
process
remov
inactiv
consid
individu
step
term
cumul
process
clearanc
factor
consid
result
obtain
human
polioviru
type
ii
canin
parvoviru
also
singl
chromatograph
step
consid
suffici
addit
inactiv
step
includ
includ
low
ph
condit
occur
part
purif
process
elut
step
see
fig
fig
ia
iia
illustr
almost
initi
charg
envelop
virus
complet
inactiv
ph
inactiv
factor
obtain
canin
parvoviru
inactiv
demonstr
human
polioviru
type
ii
h
differ
observ
resist
virus
could
partial
explain
presenc
viral
envelop
previous
mention
purifi
mab
use
immunopurif
rhbsag
elut
immunoaffin
column
use
kscn
hbsag
initi
liber
yeast
cell
nondisulfidebond
aggreg
monom
subunit
aggreg
convert
fulli
disulfidebond
particl
resembl
natur
hbsag
treatment
kscn
suggest
facilit
exchang
intrachain
interchain
within
alreadi
oxid
hbsag
polypeptid
wampler
et
al
intrachain
interchain
disulfid
linkag
dimmer
higher
multim
known
respons
stabil
correct
threedimension
structur
highli
immunogen
hbsag
particl
stabil
rhbsag
increas
high
concentr
kscn
combin
condit
high
temperatur
viru
inactiv
analyz
use
phase
exponenti
decay
model
take
account
process
design
carri
spike
experi
infect
sampl
viral
charg
heat
evalu
viral
reduct
sampl
desalt
fig
ib
iib
show
viral
charg
inactiv
condit
min
consid
result
possibl
conclud
protein
affin
chromatographi
follow
low
ph
treatment
abl
reduc
log
envelop
virus
howev
log
maximum
clearanc
factor
show
two
step
nonenvelop
virus
human
polioviru
type
ii
inactiv
citric
acid
ph
heat
treatment
addit
safeti
level
lrv
log
reduct
valu
sensit
limit
assay
tcid
ml
fere
robust
reduct
factor
product
cuban
hepat
b
viru
vaccin
